ID
33874
Description
Study ID:103860/269 Clinical Study ID:103860/269 (HBV-269) Study Title: Phase II study to evaluate the immunogenicity of GSK Biologicals' preservative-free Engerix-B and thiomersal-free Engerix-B vaccines compared to Engerix™-B and evaluate safety and reactogenicity of each vaccine when administered intramuscularly according to a 0, 1, 6 month schedule in healthy volunteers Patient Level Data:Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 2 Study Recruitment Status: Completed Generic Name: Hepatitis B Vaccine, Recombinant Trade Name: Engerix-B Study Indication: Hepatitis B
Keywords
Versions (1)
- 1/5/19 1/5/19 -
Copyright Holder
GlaxoSmithKline
Uploaded on
January 5, 2019
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Immunogenicity, safety and reactogenicity of preservative-free Engerix-B and thiomersal-free Engerix-B vaccines compared to Engerix™️-B
Study Conclusion
- StudyEvent: ODM
Description
Investigator Signature
Alias
- UMLS CUI-1
- C2346576
Description
I certify that I have reviewed the data in this case report form, the Adverse Events and Serious Adverse Event sections including any laboratory data (if appropriate) and that all information is complete and accurate.
Data type
date
Alias
- UMLS CUI [1,1]
- C2346576
- UMLS CUI [1,2]
- C0011008
Description
Investigator Signature
Data type
text
Alias
- UMLS CUI [1]
- C2346576
Similar models
Study Conclusion
- StudyEvent: ODM
C0008972 (UMLS CUI-2)
C0805701 (UMLS CUI [1,2])
C1706839 (UMLS CUI [1,2])
C1710677 (UMLS CUI [1,2])
C0805839 (UMLS CUI [1,2])
C0805839 (UMLS CUI [1,2])
C1142435 (UMLS CUI [1,3])
C0011008 (UMLS CUI [1,2])